- Tables of Contents (Vol. 54, No. 1~4, 2022)
-
- KMID: 2534206
- Cancer Res Treat.
- 2022 Oct;54(4):1278-1288.
-
- CITED
-
- Close
- SHARE
-
- Close
- Acknowledgment of Reviewers (2022)
-
- KMID: 2534207
- Cancer Res Treat.
- 2022 Oct;54(4):1289-1292.
-
- CITED
-
- Close
- SHARE
-
- Close
- Treating Oligometastses, Prelude or Just Hassles of Systemic Treatment
-
Lee DH
- KMID: 2534175
- Cancer Res Treat.
- 2022 Oct;54(4):951-952.
- doi: 10.4143/crt.2022.1326
-
- CITED
-
- Close
- SHARE
-
- Close
- The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non–Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors
-
Sun X, Feng Y, Zhang B, Huang W, Zhao X, Zhang H, Yue D, Wang C
- KMID: 2534181
- Cancer Res Treat.
- 2022 Oct;54(4):1017-1029.
- doi: 10.4143/crt.2021.1007
Purpose The aim of our study was to investigate the value of baseline and preoperative neutrophil-to-lymphocyte ratio (NLR) in predicting the pathological response and disease-free survival (DFS) of neoadjuvant chemotherapy alone... -
- CITED
-
- Close
- SHARE
-
- Close
- The Value of the Illness-Death Model for Predicting Outcomes in Patients with Non–Small Cell Lung Cancer
-
Chae KJ, Choi H, Jeong WG, Kim J
- KMID: 2534179
- Cancer Res Treat.
- 2022 Oct;54(4):996-1004.
- doi: 10.4143/crt.2021.902
Purpose The illness-death model (IDM) is a comprehensive approach to evaluate the relationship between relapse and death. This study aimed to illustrate the value of the IDM for identifying risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Fear of Cancer Recurrence and Its Negative Impact on Health-Related Quality of Life in Long-term Breast Cancer Survivors
-
Tran TXM, Jung SY, Lee EG, Cho H, Kim NY, Shim S, Kim HY, Kang D, Cho J, Lee E, Chang YJ, Cho H
- KMID: 2534185
- Cancer Res Treat.
- 2022 Oct;54(4):1065-1073.
- doi: 10.4143/crt.2021.835
Purpose Fear of cancer recurrence (FCR) is a common psychological issue in breast cancer (BC) survivors during early survivorship but whether the same is true among long-term survivors has yet... -
- CITED
-
- Close
- SHARE
-
- Close
- Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation
-
Wei Y, Wei C, Chen L, Liu N, Ou Q, Yin JC, Pang J, Fang Z, Wu X, Wang X, Mu D, Shao Y, Yu J, Yuan S
- KMID: 2534200
- Cancer Res Treat.
- 2022 Oct;54(4):1209-1218.
- doi: 10.4143/crt.2021.963
Purpose Neoadjuvant therapy modality can increase the operability rate and mitigate pathological risks in locally advanced cervical cancer, but treatment response varies widely. It remains unclear whether genetic alterations correlate with... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
-
Lee YP, Lee MS, Kim H, Kim JY, Ahn JS, Im YH, Park YH
- KMID: 2534192
- Cancer Res Treat.
- 2022 Oct;54(4):1130-1137.
- doi: 10.4143/crt.2021.1103
Purpose Trastuzumab has markedly improved the survival outcomes of patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer, and dual blockade of HER2 using trastuzumab and pertuzumab in... -
- CITED
-
- Close
- SHARE
-
- Close
- Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis
-
Kang S, Ryu MH, Bang YH, Kim HD, Lee HE, Kang YK
- KMID: 2534196
- Cancer Res Treat.
- 2022 Oct;54(4):1167-1174.
- doi: 10.4143/crt.2021.1040
Purpose Three years of adjuvant imatinib is the standard treatment for resected gastrointestinal stromal tumors (GISTs) with rupture, but the recurrence rate is prominently high. We aimed to investigate the... -
- CITED
-
- Close
- SHARE
-
- Close
- Lobular Carcinoma In Situ during Preoperative Biopsy and the Rate of Upgrade
-
Lee J, Ku GY, Lee H, Park HS, Ku JS, Kim JY, Park S, Park BW
- KMID: 2534186
- Cancer Res Treat.
- 2022 Oct;54(4):1074-1080.
- doi: 10.4143/crt.2021.864
Purpose There is a potential risk that lobular carcinoma in situ (LCIS) on preoperative biopsy might be diagnosed as ductal carcinoma in situ (DCIS) or invasive carcinoma in the final pathology.... -
- CITED
-
- Close
- SHARE
-
- Close
- The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer
-
Song IH, Kim YA, Heo SH, Bang WS, Park HS, Choi Yh, Lee H, Seo JH, Cho Y, Jung SW, Kim HJ, Ahn SH, Lee HJ, Gong G
- KMID: 2534190
- Cancer Res Treat.
- 2022 Oct;54(4):1111-1120.
- doi: 10.4143/crt.2021.1017
Purpose The expression of major histocompatibility complex class I (MHC I) has previously been reported to be negatively associated with estrogen receptor (ER) expression. Furthermore, MHC I expression, level of tumor-infiltrating... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Estrogen Receptor Expression Level and Hormonal Therapy on Prognosis of Early Breast Cancer
-
Yoon KH, Park Y, Kang E, Kim EK, Kim JH, Kim SH, Suh KJ, Kim SM, Jang M, Yun BL, Park SY, Shin HC
- KMID: 2534187
- Cancer Res Treat.
- 2022 Oct;54(4):1081-1090.
- doi: 10.4143/crt.2021.890
Purpose Estrogen receptor (ER) expression in breast cancer plays an essential role in carcinogenesis and disease progression. Recently, tumors with low level (1%-10%) of ER expression have been separately defined... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term Exposure to PM10 Increases Lung Cancer Risks: A Cohort Analysis
-
Lee HW, Kang SC, Kim SY, Cho YJ, Hwang S
- KMID: 2534182
- Cancer Res Treat.
- 2022 Oct;54(4):1030-1037.
- doi: 10.4143/crt.2021.1030
Purpose Although lung cancer incidences in female never-smokers have increased, few studies focus on explicit investigation. We aimed to investigate the relationship between long-term exposure to ambient particulate matter sized 10... -
- CITED
-
- Close
- SHARE
-
- Close
- Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability‒High Colon Cancer
-
Hyung J, Cho EJ, Kim J, Kim JH, Kim JE, Hong YS, Kim TW, Sung CO, Kim SY
- KMID: 2534197
- Cancer Res Treat.
- 2022 Oct;54(4):1175-1190.
- doi: 10.4143/crt.2021.1133
Purpose Recent clinical trials have reported response rates < 50% among patients treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors for microsatellite instability‒high (MSI-H) colorectal cancer (CRC), and factors... -
- CITED
-
- Close
- SHARE
-
- Close
- Reclassification of Five BRCA1/2 Variants with Unknown Significance Using Complex Functional Study
-
Bozsik A, Papp J, Grolmusz VK, Patócs A, Oláh E, Butz H
- KMID: 2534177
- Cancer Res Treat.
- 2022 Oct;54(4):970-984.
- doi: 10.4143/crt.2021.1078
Purpose While BRCA1/2 genes are commonly investigated, variants of unknown significance (VUS) and variants with potential splice effect are still being detected and they represent a substantial challenge in genetic... -
- CITED
-
- Close
- SHARE
-
- Close
- Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers
-
Noh JJ, Kim MK, Choi MC, Lee JW, Park H, Jung SG, Joo WD, Song SH, Lee C
- KMID: 2534199
- Cancer Res Treat.
- 2022 Oct;54(4):1200-1208.
- doi: 10.4143/crt.2021.828
Purpose This study was to investigate the frequency of mismatch repair deficiency/high microsatellite instability (MMRd/MSI-H) in gynecologic malignancies and the efficacy of immune checkpoint inhibitors (ICIs) in patients with recurrent gynecologic... -
- CITED
-
- Close
- SHARE
-
- Close
- Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer
-
Park JS, Shin S, Lee YJ, Lee ST, Nam EJ, Han JW, Lee SH, Kim TI, Park HS
- KMID: 2534189
- Cancer Res Treat.
- 2022 Oct;54(4):1099-1110.
- doi: 10.4143/crt.2021.978
Purpose The aim of the study was to evaluate the clinical implication of multigene panel testing of beyond BRCA genes in Korean patients with BRCA1/2 mutation-negative breast cancer. Materials and Methods... -
- CITED
-
- Close
- SHARE
-
- Close
- Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion
-
Kim YJ, Ji WJ, Lee JC, Chun SM, Choi CM
- KMID: 2534178
- Cancer Res Treat.
- 2022 Oct;54(4):985-995.
- doi: 10.4143/crt.2021.857
Purpose This study was to evaluate anti-tumor efficacy of osimertinib in patients positive for acquired epidermal growth factor receptor (EGFR) T790M mutation in liquid biopsy using plasma, bronchoalveolar lavage fluid (BALF)... -
- CITED
-
- Close
- SHARE
-
- Close
- Prevalence of Psychological Symptoms in Patients Undergoing Pancreatoduodenectomy and Results of a Distress Management System: A Clinic-Based Study
-
Kang MJ, Yu ES, Kang YH, Park HM, Park SJ, Kim SW, Kim JH, Han SS
- KMID: 2534193
- Cancer Res Treat.
- 2022 Oct;54(4):1138-1147.
- doi: 10.4143/crt.2021.842
Purpose Patients undergoing pancreatoduodenectomy are a high-risk group that requires psychosocial support. This study retrospectively reviewed the prevalence of psychological symptoms in patients undergoing pancreatoduodenectomy for periampullary neoplasm and the psychosocial... -
- CITED
-
- Close
- SHARE
-
- Close
- Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy
-
Seol A, Yim GW, Chung JY, Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS
- KMID: 2534201
- Cancer Res Treat.
- 2022 Oct;54(4):1219-1229.
- doi: 10.4143/crt.2021.1010
Purpose This study aimed to identify patients who would benefit from third and subsequent lines of chemotherapy in recurrent epithelial ovarian cancer (EOC). Materials and Methods Recurrent EOC patients who received... -
- CITED
-
- Close
- SHARE
-
- Close
